Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research note issued on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

BLPH opened at $0.04 on Wednesday. The company’s 50 day simple moving average is $0.04 and its 200 day simple moving average is $0.05. Bellerophon Therapeutics has a 1 year low of $0.03 and a 1 year high of $0.10. The stock has a market capitalization of $440,388.00, a PE ratio of -0.04 and a beta of 0.70.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.